Bendamustine: A Viewpoint by Michael Herold

Herold, M.
March 2001
Drugs;Mar2001, Vol. 61 Issue 5, p639
Academic Journal
Provides information on the use and effectiveness of bendamustine in the palliative treatment of non-Hodgkin's lymphomas (NHL). Development of the drug; Testing of the drug; Toxicity profile of the drug.


Related Articles

  • 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Saven, Alan; Foon, Kenneth A.; Piro, Lawrence D.; Saven, A; Foon, K A; Piro, L D // Annals of Internal Medicine;9/15/94, Vol. 121 Issue 6, p430 

    Provides information on a study that used 2-Chlorodeoxyadenosine for the treatment of several patients with Langerhans-cell histiocytosis. Methodologies used; Results and discussion.

  • Multidrug regimen boosts responses to bexarotene. Guttman, Cheryl // Dermatology Times;Dec2001, Vol. 22 Issue 12, p18 

    Focuses on improvement of the response rate of patients with cutaneous T-cell lymphoma (CTCL) to bexarotene. Purpose of current treatment of CTCL; Management of treatment-related metabolic effects; Dosage of bexarotene for patients with advanced disease.

  • Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Fisher, Richard I.; DeVita, Vincent T.; Hubbard, Susan M.; Longo, Dan L.; Wesley, Robert; Chabner, Bruce A.; Young, Robert C.; Fisher, R I; DeVita, V T Jr; Hubbard, S M; Longo, D L; Wesley, R; Chabner, B A; Young, R C // Annals of Internal Medicine;Mar83, Vol. 98 Issue 3, p304 

    A new treatment program was developed in an attempt to increase the complete remission rate and survival of previously untreated patients with advanced stages of diffuse aggressive lymphomas. A flexible number of cycles of ProMACE chemotherapy (prednisone, methotrexate, doxorubicin,...

  • ODAC denies accelerated approval for pixantrone to treat NHL. Harris, Jason // Hem/Onc Today;4/25/2010, Vol. 11 Issue 8, p1 

    The article reports on the decision of the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee to reject pixantrone for the treatment of non-Hodgkin's lymphoma.

  • Alemtuzumab/pentostatin.  // Reactions Weekly;4/17/2010, Issue 1297, p9 

    The article describes the case of a 60-year-old woman who developed Epstein Barr virus-positive diffuse large B-cell lymphoma and subsequently died while receiving treatment with pentostatin and alemtuzumab.

  • Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas. Soubeyran, P; Hostein, I; Debled, M; Eghbali, H; Soubeyran, I; Bonichon, F; Astier-Gin, T; Hœrni, B // British Journal of Cancer;11/1/99, Vol. 81 Issue 5, p860 

    Bcl-2, the gene over-expressed in follicular lymphomas (FL), is able to block chemotherapy-induced apoptosis. Consequently, we wondered whether bcl-2/IgH expression variations during treatment of FL could predict the outcome of patients with t(14;18)-bearing FL. For this purpose, we used a...

  • Bexarotene tabbed for localized CTCL. Hannapel, Coriene E. // Dermatology Times;Jun2002, Vol. 23 Issue 6, p50 

    Focuses on the effectiveness of bexarotene gel for the treatment of early-stage cutaneous T-cell lymphoma. Suitability of the drug for long-term treatment; Efficacy of the gel for patients having localized disease; Percentage of patient response rate to treatment.

  • ONCOLOGY BRIEFS.  // Dermatology Times;Jul2003, Vol. 24 Issue 7, p35 

    Reports issues related to oncology as of July 2003. Approaches to advanced tumors; Development of drugs for cutaneous lymphoma.

  • Chemotherapy for large-cell lymphoma: optimism and caution. Coleman, Morton; Coleman, M // Annals of Internal Medicine;Jul85, Vol. 103 Issue 1, p140 

    Editorial. Studies the stepwise theories and principles of chemotherapy for the treatment of patients with large-cell lymphoma. Eventuality of cure for almost all patients with large-cell lymphoma; Description of chemotherapy regimens beneficial for disease-free survival rate; Role of drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics